LINC01748: A Potential Drug Target and Biomarker (G105378763)

Target Name: LINC01748

NCBI ID: G105378763

LINC01748

Other Name(s): Long intergenic non-protein coding RNA 1748 | long intergenic non-protein coding RNA 1748

LINC01748: A Potential Drug Target and Biomarker

LINC01748 is a long intergenic non-protein coding RNA (lncRNA) with a unique gene expression pattern in the human body. It has been identified as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we will explore the biology and potential clinical applications of LINC01748.

The Identification of LINC01748

LINC01748 was first identified using transcriptomics techniques as a highly expressed lncRNA in various tissues and cell types, including brain, heart, and muscle. It had a unique gene expression pattern, with a strong expression in the brain and a weaker expression in the heart and muscle. The expression pattern of LINC01748 was also observed in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The Potential Drug Target

LINC01748 has been identified as a potential drug target due to its unique expression pattern in various diseases. Cancer is a leading cause of death worldwide, and there is a significant need for new therapeutic approaches to treat this disease. LINC01748 has been shown to be involved in the regulation of cell growth and survival, which are critical processes in cancer development. Therefore, LINC01748 could be a valuable target for cancer therapy.

The Potential Biomarker

LINC01748 has also been identified as a potential biomarker for several diseases. Neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, are characterized by the progressive loss of brain cells and progressive cognitive decline. There is a significant need for new diagnostic tools and therapeutic approaches to treat these diseases. LINC01748 has been shown to be involved in the regulation of neurodegenerative diseases, and its expression pattern may be a useful biomarker for these diseases.

The Potential Therapeutic Applications

LINC01748 has been shown to be involved in several therapeutic applications, including cancer, neurodegenerative diseases, and autoimmune disorders. Cancer is a leading cause of death worldwide, and there is a significant need for new therapeutic approaches to treat this disease. LINC01748 has been shown to be involved in the regulation of cell growth and survival, which are critical processes in cancer development. Therefore, LINC01748 could be a valuable target for cancer therapy.

Neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, are characterized by the progressive loss of brain cells and progressive cognitive decline. There is a significant need for new diagnostic tools and therapeutic approaches to treat these diseases. LINC01748 has been shown to be involved in the regulation of neurodegenerative diseases, and its expression pattern may be a useful biomarker for these diseases.

Autoimmune disorders are a significant public health issue, characterized by the immune system attacking the body's own tissues. There is a significant need for new diagnostic tools and therapeutic approaches to treat these disorders. LINC01748 has been shown to be involved in the regulation of autoimmune disorders, and its expression pattern may be a useful biomarker for these disorders.

Conclusion

In conclusion, LINC01748 is a long intergenic non-protein coding RNA with a unique gene expression pattern in the human body. Its unique expression pattern has led to its identification as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to explore the biology and clinical applications of LINC01748.

Protein Name: Long Intergenic Non-protein Coding RNA 1748

The "LINC01748 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01748 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets